Showing results (201-210 of 399) with videos related to

Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 7, 2012
Bortezomib added to daunorubicin and cytarabine during induction therapy and to intermediate-dose cytarabine for consolidation in patients with previously untreated acute myeloid leukemia age 60 to 75 years: CALGB (Alliance) study 10502Eyal C Attar, Jeffrey L Johnson, Philip C Amrein, et al.
Blood|October 7, 2024
Asciminib plus dasatinib and prednisone for Philadelphia chromosome-positive acute leukemiaMarlise R Luskin, Mark A Murakami, Julia Keating, et al.
Blood Advances|October 17, 2017
A phase 2 study incorporating sorafenib into the chemotherapy for older adults with FLT3-mutated acute myeloid leukemia: CALGB 11001Geoffrey L Uy, Sumithra J Mandrekar, Kristina Laumann, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Experimental Hematology|December 18, 2021
Transcriptional differences between JAK2-V617F and wild-type bone marrow cells in patients with myeloproliferative neoplasmsDebra Van Egeren, Baransel Kamaz, Shichen Liu, et al.
Cancer Immunology Research|April 13, 2016
Autophagy Inhibition Dysregulates TBK1 Signaling and Promotes Pancreatic InflammationShenghong Yang, Yu Imamura, Russell W Jenkins, et al.
Cancer|May 1, 2015
Health care utilization and end-of-life care for older patients with acute myeloid leukemiaAreej R El-Jawahri, Gregory A Abel, David P Steensma, et al.
Cancer|January 3, 2014
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808Jonathan E Kolitz, Stephen L George, Don M Benson, et al.
American Journal of Hematology|August 4, 2018
Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study resultsJorge E Cortes, B Douglas Smith, Eunice S Wang, et al.
The Lancet. Haematology|July 9, 2017
Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE studyHagop M Kantarjian, Daniel J DeAngelo, Anjali S Advani, et al.
Pageof 40